CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Gemini Therapeutics (GMTX) vaulted by volume and buy ratings

By Andrew Knoll

00:04, 16 December 2021

Gemini Therapeutics made large stock gains - Photo: Shutterstock

Gemini Therapeutics (GMTX), a clinical-stage biotech enterprise focused on macular degeneration and other ocular treatments, finished the day up 23% after even heavier gains and a massive spike in trading volume in premarket and early trading.

Trade volume soared more than 2,000%, seemingly based on buy ratings and ambitious target prices from analysts. Multiple reports indicated that the six analysts monitoring the stock have all issued buy ratings. 

The consensus was reached on Wednesday when HC Wainwright issued a buy rating, a day after Zacks Investment Research shifted its rating from hold to buy. Price targets were as high as $20 on a stock that closed at $2.99 on Wednesday.

Promise spurs prosperity

In the note from HC Wainwright, obtained by Yahoo! Finance, analyst Matthew Caufield described the lead candidate in Gemini’s pipeline, GEM103, as a platform catalyst.

Thus far, clinical trial results from its Phase 2a study have been encouraging in terms of both efficacy and patient tolerance.

Caulield also touted GEM307, another treatment in Gemini’s pipeline, as offering further potential to advance treatments rooted in Complement Factor H (CFH) regulation, an approach that has created intrigue along with ocular and retinal gene therapies. 


1.09 Price
+0.090% 1D Chg, %
Long position overnight fee -0.0080%
Short position overnight fee -0.0003%
Overnight fee time 22:00 (UTC)
Spread 0.00006


0.63 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168


2,196.02 Price
+0.930% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 6.00


239.02 Price
+1.900% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.14

Market potential

Age-related macular degeneration impacts roughly one out of every three Americans aged 70 or older.

The global market size for treatments of macular degeneration and related ocular issues, Gemini’s speciality, was estimated at $7.75bn (£5.84bn) in 2020.

With a compound annual growth rate approaching 7%, it could approach $11.5bn (£8.7bn) in 2026. In the US, the CAGR was closer to 9%, with the US already being the largest market in the world for treatments of age-related macular degeneration.


Read more: Cognition Therapeutics prices .2m IPO at per share

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading